(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths - 2Dominating the Remote Work Way of life: Individual Systems
- 34 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- 4Obamacare enrollment declines as US subsidies expire
- 5Top Pastry: What's Your Sweet Treat of Decision?
- The beauty advent calendar boom is here. Sephora kids are all in.
- Viable Monetary Tips to Advance Your Monetary Circumstance
- Flu illness count nears 5 million, with New York City among the hardest hit
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Wegmans recalls mixed nuts over salmonella contamination fears
- 6 Exemplary Mexican Dishes
- State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- My skin feels drier, my lips thinner and my makeup heavier. How do I adjust my routine for aging skin?
